AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02056301
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
Trial: NCT04584567
Drug: Doxycyclin
RxNorm normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily (100mg)
Trial: NCT00004317
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm descriptions
Trial: NCT00004317
Drug: Spiramycin
RxNorm normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Spiramycin is administered before the fetal diagnosis is made.
Trial: NCT00004317
Drug: Sulfadiazine
RxNorm normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm descriptions
Trial: NCT01809626
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02985736
Drug: Topicort Topical Spray
RxNorm normalized name: desoximetasone Topical Spray [Topicort]
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00374777
Drug: zolpidem MR
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00374777
Drug: nitrazepam
RxNorm normalized name: nitrazepam
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01390246
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 150 mg tablet
Trial: NCT01266759
Drug: NuvaRing
RxNorm normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
Trial: NCT01266759
Drug: Norethisterone Acetate tablets - 5mg
RxNorm normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
Trial: NCT04034589
Drug: Pyrotinib combined with fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
Trial: NCT02669186
Drug: Bupivacaine + Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
Trial: NCT02669186
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
Trial: NCT03971643
Drug: vilobelimab
RxNorm normalized name: Vilobelimab
DrugBank: Vilobelimab (DB16416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of vilobelimab diluted in sodium chloride.
Trial: NCT01485952
Drug: SEN0014196 (Low Dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg once daily administration (immediate release capsule)
Trial: NCT01485952
Drug: SEN0014196 (High Dose)
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once daily administration (immediate release capsule)
Trial: NCT00078390
Drug: S-3304
RxNorm normalized name: S-3304
DrugBank: S-3304 (DB12149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
Trial: NCT00582582
Drug: Docetaxel plus doxercalciferol
RxNorm normalized name: Doxercalciferol
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
Trial: NCT00582582
Drug: Docetaxel plus placebo
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
Trial: NCT02279641
Drug: allopurinol 300 mg
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02510157
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: active comparator
Trial: NCT02510157
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
Trial: NCT00930358
Drug: MEOPA
RxNorm normalized name: homeopathic drugs
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anaesthetic gaz inhalation
Trial: NCT02422030
Drug: Trilipix 135mg
RxNorm normalized name: Trilipix 135mg Delayed-Release Capsule
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03639480
Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
RxNorm normalized name: amlodipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Trial: NCT03639480
Drug: Amlodipine 10mg+Valsartan 160mg
RxNorm normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Amlodipine 10mg+Valsartan 160mg
Trial: NCT03639480
Drug: Valsartan 160mg+Atorvastatin 40mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160mg+Atorvastatin 40mg
Trial: NCT00003335
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
Trial: NCT00003335
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine begin on day -2 and continue for 6 months.
Trial: NCT00003335
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: melphalan IV for three days on days -4 to -2
Trial: NCT00003335
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
Trial: NCT00718718
Drug: CNTO 136 100 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
Trial: NCT00718718
Drug: CNTO 136 50 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
Trial: NCT00718718
Drug: CNTO 136 25 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
Trial: NCT02358824
Drug: CKD-828
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)
Trial: NCT02358824
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)
Trial: NCT02358824
Drug: S-amlodipine
RxNorm normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)
Trial: NCT00965848
Drug: Doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Trial: NCT03646344
Drug: Heme Arginate 25 MG/ML
RxNorm normalized name: heme arginate 25 MG/ML
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Trial: NCT03646344
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Trial: NCT04231435
Drug: Fedratinib
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT04231435
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04231435
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT00006019
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006019
Drug: sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396734
Drug: Provigil (Modafinil)
RxNorm normalized name: modafinil Oral Tablet [Provigil]
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increase from 100mg to 400mg during 1 month of treatment
Trial: NCT00396734
Drug: Topamax (Topiramate)
RxNorm normalized name: topiramate Oral Tablet [Topamax]
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increase from 25mg to 200mg in one month (double every week)
Trial: NCT04150575
Drug: HLX10+Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
Trial: NCT03403634
Drug: Rintatolimod
RxNorm normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01997775
Drug: METFORMIN
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
Trial: NCT03058406
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
Trial: NCT04018872
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
Trial: NCT02877485
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sprays sprayed to both nostrils daily for 42 days.
Trial: NCT01181895
Drug: Vilanterol
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Trial: NCT01181895
Drug: Salmeterol Inhalation Powder
RxNorm normalized name: Salmeterol Inhalation Powder
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Trial: NCT00821691
Drug: Amantadin
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadin caps
Trial: NCT02120339
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177344
Drug: Low dose of Ipratropium bromide
RxNorm normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One puff, 4 times daily by oral inhalation
Trial: NCT02177344
Drug: High dose of Ipratropium bromide
RxNorm normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One puff, 4 times daily by oral inhalation
Trial: NCT02177344
Drug: Atrovent
RxNorm normalized name: Atrovent
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two puffs, 4 times daily by oral inhalation
Trial: NCT03319043
Drug: Chanqin granules
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
Trial: NCT00452504
Drug: SRA-444
RxNorm normalized name: SRA-737
DrugBank: SRA-737 (DB16876)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 1
Trial: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 2
Trial: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 3
Trial: NCT01363323
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02066298
Drug: Mometasone 220mcg BID
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone is an ICS
Trial: NCT02066298
Drug: Tiotropium Respimat 5mcg QD
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium is a LMA
Trial: NCT05095480
Drug: Red Yeast Rice Pill
RxNorm normalized name: red yeast rice Pill
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking Lesstat
Trial: NCT02294292
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
Trial: NCT02294292
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction
Trial: NCT01519518
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 units/kg body weight intravenous
Trial: NCT01519518
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Trial: NCT00013897
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00013897
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00013897
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01169857
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
Trial: NCT03129347
Drug: Nalmefene
RxNorm normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
Trial: NCT02934139
Drug: Cavosonstat
RxNorm normalized name: Cavosonstat
DrugBank: Cavosonstat (DB14775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR modulator that stabilizes CFTR
Trial: NCT01679119
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1
Trial: NCT01679119
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 IV given day 1
Trial: NCT01679119
Drug: Inotuzumab Ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
Trial: NCT01679119
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
Trial: NCT01629082
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01629082
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02564198
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT00982319
Drug: Broccoli sprout extract
RxNorm normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µmols of sulforaphane (dissolvable)
Trial: NCT00982319
Drug: Mango juice
RxNorm normalized name: mango juice
DrugBank: Mango (DB10657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL of mango juice
Trial: NCT01922596
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00030550
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00151801
Drug: interferon-beta 1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03788889
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine infusion
Trial: NCT03788889
Drug: Phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital intravenous injection
Trial: NCT03788889
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care